Related Experiment Video
Updated: Jun 30, 2026
Establishing a Physiologic Human Vascularized Micro-Tumor Model for Cancer Research
Published on: September 15, 2023
Organoids, organ-on-a-chip, and microtumors: Biomimetic 3D tumor models advancing drug development and precision
Mengjiao Xia1,2,3,4, Guohua Wu5, Di Wu2,3,6,7
1Clinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu 610041, China.
Abstract:
The rising global cancer burden underscores the urgent need for more effective drug development and personalized therapies. Conventional screening models, such as 2D cell lines and patient-derived xenografts, fail to adequately recapitulate the architecture, heterogeneity, and microenvironment of human tumors, limiting their clinical translatability. In response, human-derived biomimetic platforms have emerged. Organoids and organ-on-a-chip preserve key tumor genetics and stimulate dynamic, physiologically relevant microenvironments, whereas microtumors are distinguished by high biological fidelity. Microtumors uniquely retain the native tumor ecosystem, capture a broader spectrum of intratumoral heterogeneity, and, critically, maintain a functional immune microenvironment. Together, these systems enable drug screening that more faithfully reflects the clinical context, with strong potential to raise drug development success rates and support individualized therapy. This review consolidates the cutting-edge advancements and critical challenges associated with these models in drug development, precision medicine, and clinical translation. Furthermore, it envisions how Artificial Intelligence (AI) can drive its intelligent evolution, aiming to provide a robust evidentiary basis and practical reference for research and clinical practice, thereby propelling the field of precision oncology into a new era.
Insights
Advanced biomimetic models like organoids and microtumors offer superior cancer drug development platforms. These human-derived systems better mimic tumor complexity and microenvironments, improving drug screening accuracy and advancing precision oncology.
Area of Science:
- Oncology
- Biomedical Engineering
- Translational Medicine
Background:
- Global cancer burden necessitates improved drug development and personalized therapies.
- Conventional models (2D cell lines, xenografts) lack tumor architecture, heterogeneity, and microenvironment fidelity, limiting clinical translation.
- Human-derived biomimetic platforms are emerging as superior alternatives.
Purpose of the Study:
- To review advancements and challenges in biomimetic models for cancer drug development and precision medicine.
- To highlight the potential of organoids, organ-on-a-chip, and microtumors in enhancing drug screening and clinical translation.
- To explore the role of Artificial Intelligence (AI) in advancing these models for precision oncology.
Main Methods:
- Review of current literature on organoids, organ-on-a-chip, and microtumors in cancer research.
- Analysis of the biological fidelity and clinical translatability of these advanced models.
- Discussion on the integration of AI for optimizing biomimetic platforms.
Main Results:
- Organoids and organ-on-a-chip preserve tumor genetics and simulate relevant microenvironments.
- Microtumors exhibit high biological fidelity, retaining native tumor ecosystems and functional immune microenvironments.
- These models enable drug screening that more accurately reflects the clinical context, potentially increasing success rates.
Conclusions:
- Biomimetic platforms significantly improve drug development and personalized therapy for cancer.
- Microtumors offer unique advantages in recapitulating tumor heterogeneity and immune interactions.
- AI integration promises to further enhance these models, driving precision oncology forward.
